Literature DB >> 9463836

Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression.

J H Thakore1, C Barnes, J Joyce, S Medbak, T G Dinan.   

Abstract

To date, there appears to be no consensus of opinion as to whether the adrenal glands are hyperresponsive during depression and, if so, whether this a state-dependent phenomenon. We aimed to determine the effects of antidepressant treatment on ACTH-induced cortisol responses in patients with melancholic depression. Seven female patients with DSM-III-R major depressive disorder, non-psychotic, melancholic subtype, were evaluated using the following rating scales: the Hamilton Depression Rating Scale, the Montgomery-Asberg Depression Rating Scale and the Newcastle Endogenicity Scale. All subjects were then given an intravenous bolus dose (250 micrograms) of tetracosactrin, a potent stimulus of adrenocortical hormone secretion. Plasma levels of cortisol were measured at times 0, + 30, + 60, + 90, + 120 and + 180 min. Patients were then randomised to receive either 50 mg of sertraline or 20 mg of paroxetine (both of which are selective serotonin re-uptake inhibitors) and were re-tested while medication-free. Treatment resulted in a significant decrease in delta (the difference between the baseline values and the maximum increase post-ACTH administration) cortisol values of 1633.3 +/- 378.5 nmol/l vs. 595.1 +/- 207.7 nmol/l. Successful pharmacological treatment of major depressive disorder appears to be associated with a reduction in ACTH-induced cortisol release in drug-free patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9463836     DOI: 10.1016/s0165-1781(97)00106-6

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

Review 1.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

2.  Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer.

Authors:  Aliza Z Weinrib; Sandra E Sephton; Koen Degeest; Frank Penedo; David Bender; Bridget Zimmerman; Clemens Kirschbaum; Anil K Sood; David M Lubaroff; Susan K Lutgendorf
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

Review 3.  Sex differences in the hypothalamic-pituitary-adrenal axis: An obstacle to antidepressant drug development?

Authors:  Nikolaos Kokras; Georgia E Hodes; Debra A Bangasser; Christina Dalla
Journal:  Br J Pharmacol       Date:  2019-06-26       Impact factor: 8.739

4.  Effects of antidepressant drug therapy with or without physical exercise on inflammatory biomarkers in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Beatriz Monteiro Fernandes; Estêvão Scotti-Muzzi; Márcio Gerhardt Soeiro-de-Souza
Journal:  Eur J Clin Pharmacol       Date:  2021-10-27       Impact factor: 2.953

5.  Mapping of hormones and cortisol responses in patients after Lyme neuroborreliosis.

Authors:  Ivar Tjernberg; Martin Carlsson; Jan Ernerudh; Ingvar Eliasson; Pia Forsberg
Journal:  BMC Infect Dis       Date:  2010-02-05       Impact factor: 3.090

Review 6.  Stress, depression, and coronary artery disease: modeling comorbidity in female primates.

Authors:  Carol A Shively; Dominique L Musselman; Stephanie L Willard
Journal:  Neurosci Biobehav Rev       Date:  2008-06-24       Impact factor: 8.989

7.  Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder.

Authors:  María Eugenia Hernandez; Danelia Mendieta; Mayra Pérez-Tapia; Rafael Bojalil; Iris Estrada-Garcia; Sergio Estrada-Parra; Lenin Pavón
Journal:  Clin Dev Immunol       Date:  2013-11-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.